Navigation Links
Pressure BioSciences, Inc. Announces Move to New Corporate Offices
Date:3/10/2008

SOUTH EASTON, Mass., March 10 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) today announced that it has moved its corporate offices to 14 Norfolk Avenue in South Easton, Massachusetts. This move was necessary to accommodate the Company's transition from an early-stage, research and development company to a fully commercial operation. Richard T. Schumacher, PBI's Founder, President, and CEO commented: "We now have approximately 5,500 square feet, with sufficient office, conference, engineering lab, and storage space to allow us to better develop our infrastructure to support our PCT product commercialization. In addition, the 18 month lease, with equal term extension, gives us the financial flexibility we require as we continue to grow our business and carefully manage our financial resources". The Company's primary research and development facility continues to be located at 6 Gill Street in Woburn, MA.

Corporate address:

Pressure BioSciences, Inc

14 Norfolk Avenue

South Easton, MA 02375

(t) (508) 230-1828

(f) (508) 230-1829

Research and Development Center

Pressure BioSciences, Inc

6 Gill Street, Suite H

Woburn, MA 01801

(t) (781) 932-9477

(f) (781) 932-9294

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com

Investor Contacts:

Richard T. Schumacher, President & CEO Pressure BioSciences, Inc.

Edward H. Myles,

Senior Vice President of Finance & CFO (T) 508-230-1828


'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Specific antagonism lowers blood pressure
3. Doctors Often Miss High Blood Pressure in Kids
4. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
5. Hospitals Could Improve Outcomes for Patients and Save Millions According to Hill-Rom 10th Annual Pressure Ulcer Survey
6. Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in San Antonio
7. AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure
8. Memory tasks require more coordinated brain blood flow for people with high blood pressure
9. Pressure to Promote Healthier Eating to Cause Minor Growing Pains for Kids Licensed Foods and Beverages
10. High Blood Pressure & Stroke Attack was the Focus for the Third Stop of the 2007 Empowerment Tour for a Healthier Life
11. Daytime, Nighttime Blood Pressure Both Important
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... 26, 2017 , ... The American Parkinson Disease Association’s ... grant submissions all vying for nearly $1,000,000 in funding that will be awarded ... American Parkinson Disease Association (APDA) is focused on advancing scientific research that will ...
(Date:5/26/2017)... ... May 26, 2017 , ... The Radiology Business Management ... on current legislative activity and the latest regulatory concerns impacting RBMA members. The ... 10, and will continue through Monday, Sept. 11, at the Ritz-Carlton, Tysons Corner ...
(Date:5/26/2017)... ... 26, 2017 , ... Somnoware, a leading provider of digital ... its Somnoware Sleep Device Interface (SDI). Somnoware SDI is a sleep device integration ... platform, initializing devices and importing studies are just one-click operations. This plugin streamlines ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... premium delicatessen foods, is sharing bold recipes for Memorial Day entertaining that are ... menus. , “Boar’s Head fresh sliced meats and cheeses featured in these ...
(Date:5/26/2017)... ... May 26, 2017 , ... On May 24, the Congressional ... passed the U.S. House on May 4, would result in 23 million Americans losing ... implementation of the 2010 Patient Protection and Affordable Care Act (ACA). , “It ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... Clarius Mobile Health, a digital healthcare ... this week at the American Congress of Obstetricians ... San Diego, CA from May ... perfect tool for clinicians to easily confirm pregnancy, ... pregnancy-related complications like ectopic pregnancy and placenta previa," ...
(Date:5/4/2017)... 4, 2017  A new tight-tolerance microextrusion medical ... highly-engineered materials, is being launched by Natvar, a ... developed in recent years to service a wide ... applications. More expensive materials such as glass and ... due to their ability to consistently hold tolerances. ...
(Date:5/3/2017)... ROCKVILLE, Md. , May 3, 2017 /PRNewswire/ ... revenue growth of nine percent next year and ... solid organ and hematopoietic stem cell (HSCT) or ... and donor. Molecular testing technologies are well-suited for this ... healthcare-only market research publisher Kalorama Information. The various ...
Breaking Medicine Technology: